Randomized Pilot Study of a Keratin-based Topical Cream for Radiation Dermatitis in Breast Cancer Patients
Technology in Cancer Research & Treatment · 2024-01 · 23
DOI: 10.1177/15330338231222137 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 08.01.2024. Verfasst von Karen M Winkfield und 7 weiteren Autor:innen. Beteiligte Einrichtung: Meharry-Vanderbilt Alliance, Nashville, TN, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiodermatitis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Wake Forest Baptist Comprehensive Cancer Center Clinical Protocol and Data Management Shared Resource, supported by the National Cancer Institute’s Cancer Cent…, KeraNetics LLC.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Radiotherapy (RT) is commonly used in the treatment of breast cancer and often, despite advances in fractionated dosing schedules, produces undesirable skin toxicity. The purpose of this study was to evaluate the feasibility of using a keratin-based topical cream, KeraStat® Cream (KC; KeraNetics, Inc., Winston Salem, NC, USA) to manage the symptoms of radiation dermatitis (RD) in breast cancer patients undergoing RT. Materials and Methods: A total of 24 subjects were enrolled on this single-center, randomized, open-label study. Participants were randomly assigned to KC or standard of care (SOC, patient's choice of a variety of readily available creams or moisturizers). Patients were asked to apply the assigned treatment to the irradiated area twice daily, beginning with day 1 of RT, through 30 days post-RT. The primary outcome was compliance of use. Secondary outcomes included safety and tolerability of KC, as well as RD severity assessed using the Radiation Therapy Oncology Group (RTOG) scale and the patient-reported Dermatology Life Quality Index (DLQI).
Results
All subjects in the KC group were assessed as compliant with no adverse events. The rate of RTOG Grade 2 RD was lower in the KC group (30.8%) compared to the SOC group (54.5%, P = .408). At the final RT visit, the mean RTOG RD score was lower in the KC group (1.0) versus the SOC group (1.4). Similarly, patient-reported quality of life measured by the DLQI at the end of RT was improved in the KC group (mean 4.25, small effect) versus the SOC group (mean 6.18, moderate effect, P = .412).
Conclusions
KC was safe and well tolerated with no adverse events. Though efficacy measures were not powered to draw definitive conclusions, trends and clinical assessments suggest that there is a benefit of using KC compared to SOC for breast cancer patients treated with RT, and a larger powered study for efficacy is warranted. Trial Registry: This clinical trial is registered as NCT03374995 titled KeraStat(R) Cream for Radiation Dermatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meharry-Vanderbilt Alliance, Nashville, TN, USA.
- Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA.
- KeraNetics, Inc., Winston Salem, NC, USA.
- Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest School of Medicine, Winston Salem, NC, USA.
ORCID-Profile: Ryan T Hughes, Luke R Burnett
Förderung
- NCI NIH HHS
- Wake Forest Baptist Comprehensive Cancer Center Clinical Protocol and Data Management Shared Resource, supported by the National Cancer Institute’s Cancer Cent…
- KeraNetics LLC
Zitieren
APA
Winkfield, K. M., Hughes, R. T., Brown, D. R., Clohessy, R. M., Holder, R. C., Russell, G. B., Rejeski, A. F., & Burnett, L. R. (2024). Randomized Pilot Study of a Keratin-based Topical Cream for Radiation Dermatitis in Breast Cancer Patients. Technology in Cancer Research & Treatment, 23. https://doi.org/10.1177/15330338231222137
Vancouver
Winkfield KM, Hughes RT, Brown DR, Clohessy RM, Holder RC, Russell GB, et al. Randomized Pilot Study of a Keratin-based Topical Cream for Radiation Dermatitis in Breast Cancer Patients. Technology in Cancer Research & Treatment. 2024;23. doi:10.1177/15330338231222137
BibTeX
@article{Winkfield2024,
author = {Winkfield, Karen M and Hughes, Ryan T and Brown, Doris R and Clohessy, Ryan M and Holder, Robert C and Russell, Gregory B and Rejeski, Alexis F and Burnett, Luke R},
title = {Randomized Pilot Study of a Keratin-based Topical Cream for Radiation Dermatitis in Breast Cancer Patients},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
volume = {23},
doi = {10.1177/15330338231222137}
}
EUVIMED